Home > Insider Trading > Filing (0001181431-13-059382)

Filing Details

Accession Number:: 0001181431-13-059382
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2013-11-18 07:59:15
Reporting Period:: 2013-11-14

Filing Date:: 2013-11-18
Accepted Time:: 2013-11-18 07:59:15
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1571498	Epizyme Inc.	EPZM	Pharmaceutical Preparations (2834)	261349956

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1479386	Ravi Viswanathan	1954 Greenspring Drive Suite 600 Timonium MD 21093		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2013-11-14	40,921	$20.91	40,921	No	4	P	Indirect	See Note 2
Common Stock	Acquisiton	2013-11-14	152,459	$19.99	193,380	No	4	P	Indirect	See Note 2
Common Stock	Acquisiton	2013-11-14	163,620	$19.04	357,000	No	4	P	Indirect	See Note 2
Common Stock	Acquisiton	2013-11-15	23,700	$20.31	380,700	No	4	P	Indirect	See Note 2
Common Stock	Acquisiton	2013-11-15	25,800	$19.31	406,500	No	4	P	Indirect	See Note 2

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See Note 2
No	4	P	Indirect	See Note 2
No	4	P	Indirect	See Note 2
No	4	P	Indirect	See Note 2
No	4	P	Indirect	See Note 2

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	6,033,240	Indirect	See Note 7

Footnotes

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $20.56 to $21.5499, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4.
The Reporting Person is a director of NEA 13 GP, LTD, which is the sole general partner of NEA Partners 13, L.P. ("NEA Partners 13"). NEA Partners 13 is the sole general partner of New Enterprise Associates 13, L.P. ("NEA 13"), which is the sole member of Growth Equity Opportunities Fund II, LLC ("GEO II"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the GEO II shares in which the Reporting Person has no pecuniary interest.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $19.57 to $20.555, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $18.71 to $19.56, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $19.955 to $20.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (5) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $19.085 to $19.825, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (6) to this Form 4.
The Reporting Person is a director of NEA 13 GP, LTD, which is the sole general partner of NEA Partners 13. NEA Partners 13 is the sole general partner of NEA 13, the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 13 shares in which the Reporting Person has no pecuniary interest.